home / stock / kymr / kymr articles

KYMR Articles, Kymera Therapeutics Inc. - From 05/08/24

Stock Information
Company Name: Kymera Therapeutics Inc.
Stock Symbol: KYMR
Market: NASDAQ
Website: kymeratx.com
Menu
KYMR KYMR Quote KYMR Short KYMR News KYMR Articles KYMR Message Board
Get KYMR Alerts

News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics to Participate in Upcoming May Investor Conferences | Benzinga

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing...
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 | Benzinga

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advanci...

Kymera Therapeutics to Participate in Upcoming March Investor Conferences | Benzinga

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancin...

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference | Benzinga

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancin...
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors | Benzinga

INVO (NASDAQ: INVO) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024 Experienced, entrepreneu...

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs | Benzinga

IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline d...

Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 | Benzinga

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancin...
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4 | Benzinga

WATERTOWN, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancin...

Kymera Therapeutics Recent Insider Activity | Benzinga

BVF PARTNERS L PIL, Board Member at Kymera Therapeutics (NASDAQ:KYMR), reported a large insider buy on November 6, according to a new SEC filing. ...

More Than $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying | Benzinga

Although U.S. stocks closed slightly higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their c...
Previous 10 Next 10